GO:1905835 cellular response to pyrimidine ribonucleotide: Nucleotide Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905835 describes how a cell changes its state or activity in response to a pyrimidine ribonucleotide stimulus, such as UTP, CTP or their derivatives [2,8].
• Pyrimidine ribonucleotides are not only building blocks of RNA but also act as signaling molecules that shape metabolism, immune cross-talk and mitochondrial gene expression [2,8].
• Cancer cells frequently rewire pyrimidine ribonucleotide metabolism to sustain proliferation and to suppress antitumor immunity [2,4].
• Key nodes include NME6, which supplies ribonucleotides for mitochondrial gene expression, and nucleotide-cycling enzymes that influence drug sensitivity [4,8].
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test whether candidate genes causally mediate cellular responses to pyrimidine ribonucleotides [2,4,8].
• The term is relevant to cancer, antiviral drug repurposing and mitochondrial disease research [5,6,8].
Description
GO:1905835, cellular response to pyrimidine ribonucleotide, is a biological process term that captures any change in a cell's state or activity, including movement, secretion, enzyme production or gene expression, that occurs as a result of a pyrimidine ribonucleotide stimulus [2,8]. Pyrimidine ribonucleotides such as uridine triphosphate (UTP) and cytidine triphosphate (CTP) are canonical RNA precursors, but they also function as signaling molecules and metabolic intermediates that can reprogram cellular behavior [2,8]. This term therefore sits at the intersection of nucleotide metabolism, RNA biology and signal transduction. For researchers, GO:1905835 matters because pyrimidine ribonucleotide availability and signaling are increasingly recognized as determinants of cancer progression, immune evasion and mitochondrial function [2,4,8]. For example, nucleotide metabolism in cancer cells can fuel a UDP-driven macrophage cross-talk that promotes immunosuppression and immunotherapy resistance. In parallel, ribonucleotide synthesis by NME6 supports mitochondrial gene expression, linking pyrimidine ribonucleotide supply to organellar gene regulation. Understanding this process also has therapeutic implications. Compounds that interfere with nucleotide cycling can overcome resistance to targeted inhibitors such as KRAS G12C inhibitors, and cellular ATP levels influence sensitivity to fluorouracil in colon cancer cells. Large-scale drug repurposing has identified modulators of nucleotide pathways as potential antivirals. Thus, GO:1905835 provides a framework for studying how pyrimidine ribonucleotide signals are sensed and translated into cellular responses.
cellular response to pyrimidine ribonucleotide At A Glance
| GO ID | GO:1905835 |
|---|---|
| GO term | cellular response to pyrimidine ribonucleotide |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates cellular changes in state or activity in response to pyrimidine ribonucleotide stimuli such as UTP or CTP [2,8] |
| Related stimuli | Pyrimidine ribonucleotides including UTP, CTP and their derivatives [2,8] |
| Representative genes | NME6, and nucleotide metabolism enzymes involved in pyrimidine ribonucleotide synthesis and cycling [4,8] |
| Disease relevance | Cancer, immunotherapy resistance, mitochondrial dysfunction and antiviral responses [2,5,6,8] |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, metabolomics, RNA-seq and mitochondrial gene expression assays [2,4,8] |
What Is GO:1905835?
In our own words, GO:1905835 refers to the collection of cellular processes triggered when a cell encounters a pyrimidine ribonucleotide stimulus. The response can include changes in gene expression, enzyme activity, secretion, movement or other activities, and it is defined by the causal link to the pyrimidine ribonucleotide rather than by a single downstream pathway [2,8].
Why Is cellular response to pyrimidine ribonucleotide Important in Cell Biology?
GO:1905835 is important because pyrimidine ribonucleotides are both essential metabolites and signaling molecules, and their dysregulation is linked to major human diseases. Cancer cells often depend on altered nucleotide metabolism to proliferate and to evade immune attack. Targeting nucleotide cycling can restore sensitivity to targeted therapies. In mitochondria, ribonucleotide synthesis by NME6 is required for mitochondrial gene expression, connecting pyrimidine ribonucleotide responses to organellar biology. Moreover, cellular ATP levels modulate fluorouracil responses in colon cancer cells, showing that nucleotide status influences chemotherapy outcomes. Therefore, studying this process can reveal biomarkers and therapeutic vulnerabilities.
• Pyrimidine ribonucleotide metabolism supports cancer cell proliferation and survival.
• UDP-driven macrophage cross-talk promotes immunosuppression and immunotherapy resistance.
• Nucleotide cycling can limit the efficacy of KRAS G12C inhibitors, and overcoming it improves responses.
• NME6-mediated ribonucleotide synthesis fuels mitochondrial gene expression.
• Cellular ATP levels influence fluorouracil sensitivity in colon cancer cells.
• Nucleotide pathway modulators have been identified as potential antiviral drugs through repurposing screens.
• Pyrimidine ribonucleotide responses intersect with fatty acid oxidation and Treg biology.
• RAS-GTP inhibition shows anticancer activity in cholangiocarcinoma, highlighting nucleotide-linked signaling.
• A2AR antagonism can augment antitumor immunity, relevant to nucleotide-driven immunosuppression.
• Understanding this process aids in designing combination therapies that target nucleotide metabolism [2,4].
What Happens During cellular response to pyrimidine ribonucleotide?
Sensing pyrimidine ribonucleotide stimuli
In simple terms: The cell first detects that pyrimidine ribonucleotide levels or signals have changed.
Cells can sense pyrimidine ribonucleotides such as UTP and CTP through metabolic and signaling pathways that monitor nucleotide pools [2,8]. For instance, NME6 is involved in ribonucleotide synthesis that supports mitochondrial gene expression, indicating that mitochondrial compartments can respond to pyrimidine ribonucleotide availability. In cancer cells, altered nucleotide metabolism generates UDP species that participate in cross-talk with macrophages, showing that pyrimidine ribonucleotide signals can be sensed in the tumor microenvironment.
Metabolic reprogramming and enzyme production
In simple terms: The cell changes its enzyme activities and metabolic fluxes in response to the stimulus.
A key outcome of the response is changes in enzyme production and metabolic flux. Nucleotide cycling can affect the efficacy of KRAS G12C inhibitors, and overcoming nucleotide cycling restores drug activity, demonstrating that pyrimidine ribonucleotide-related metabolism is dynamically regulated. In colon cancer cells, cellular ATP levels influence the response to fluorouracil through LPA receptor signaling, linking nucleotide status to chemotherapy sensitivity. These examples illustrate that pyrimidine ribonucleotide stimuli can reprogram metabolic enzymes and energy status.
Gene expression and mitochondrial gene regulation
In simple terms: The cell alters which genes are expressed, including genes needed for mitochondrial function.
Pyrimidine ribonucleotide responses can change gene expression programs. Ribonucleotide synthesis by NME6 fuels mitochondrial gene expression, meaning that the availability of pyrimidine ribonucleotides directly supports the expression of mitochondrial-encoded genes. This connects GO:1905835 to organellar gene regulation and mitochondrial function. In cancer, nucleotide metabolism can also shape immune-related gene expression in macrophages, promoting an immunosuppressive phenotype.
Immune and microenvironmental cross-talk
In simple terms: The response can influence how immune cells behave in the tumor microenvironment.
Pyrimidine ribonucleotide-driven responses are not cell-autonomous; they can affect immune cells. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk that promotes immunosuppression and immunotherapy resistance. This suggests that cellular responses to pyrimidine ribonucleotides can remodel the immune microenvironment. A2AR antagonism can induce antitumor responses and augment immunotherapy, providing a therapeutic angle on such immunosuppressive circuits.
Therapeutic modulation and drug responses
In simple terms: Drugs that alter pyrimidine ribonucleotide pathways can change how cells respond to treatment.
Because pyrimidine ribonucleotide responses influence drug sensitivity, they are therapeutic targets. KRAS G12C inhibitors can be limited by nucleotide cycling, and next-generation inhibitors overcome this to show robust preclinical and clinical activity. Fluorouracil responses in colon cancer cells depend on cellular ATP levels and LPA receptor signaling. Large-scale repurposing has identified compounds that modulate nucleotide pathways as potential antivirals. These findings highlight that manipulating pyrimidine ribonucleotide responses can alter treatment outcomes.
Key Genes Involved in GO:1905835 cellular response to pyrimidine ribonucleotide
The following genes and proteins are representative of the cellular response to pyrimidine ribonucleotide and are frequently studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NME6 | Ribonucleotide synthesis supporting mitochondrial gene expression | Links pyrimidine ribonucleotide supply to mitochondrial function |
| KRAS | GTPase signaling affected by nucleotide cycling | Nucleotide cycling limits KRAS G12C inhibitor efficacy |
| LPA4 (LPAR4) | Lysophosphatidic acid receptor influencing ATP levels and drug response | Modulates fluorouracil sensitivity in colon cancer cells |
| LPA6 (LPAR6) | Lysophosphatidic acid receptor influencing ATP levels and drug response | Modulates fluorouracil sensitivity in colon cancer cells |
| PPARγ | Nuclear receptor regulating fatty acid oxidation and Treg responses | Connects metabolic and immune responses relevant to nucleotide signaling |
| CD36 | Fatty acid transporter | Upregulated by PPARγ to support Treg responses |
| CPT1 | Fatty acid oxidation enzyme | Mediates PPARγ-driven Treg responses |
| TβRII | TGF-beta receptor subunit | N-glycan branching affects its function in Tregs |
| IL-2Rα | Interleukin-2 receptor subunit | N-glycan branching affects its function in Tregs |
| A2AR | Adenosine receptor | Antagonism induces antitumor responses and augments immunotherapy |
| RAS | Small GTPase | RAS-GTP inhibition shows anticancer activity in cholangiocarcinoma |
| NME family | Nucleoside diphosphate kinases | Related to NME6 function in ribonucleotide synthesis |
| Nucleotide metabolism enzymes | Synthesis and interconversion of pyrimidine ribonucleotides | Fuel UDP-driven macrophage cross-talk |
| Macrophage receptors | Sense UDP and mediate immunosuppression | Promote immunotherapy resistance |
| SARS-CoV-2 targets | Viral proteins affected by nucleotide pathway modulators | Identified through drug repurposing |
| ATP-dependent enzymes | Energy sensing and metabolic regulation | Influence fluorouracil response |
| Treg-associated factors | Immune regulation | Linked to metabolic and nucleotide-related pathways |
How Is cellular response to pyrimidine ribonucleotide Regulated?
The cellular response to pyrimidine ribonucleotide is regulated at multiple levels. Nucleotide cycling can modulate the efficacy of KRAS G12C inhibitors, indicating that feedback loops in pyrimidine ribonucleotide metabolism control drug sensitivity. Cellular ATP levels influence fluorouracil responses through LPA receptor signaling, showing that energy status regulates this process. NME6-mediated ribonucleotide synthesis is required for mitochondrial gene expression, suggesting that mitochondrial demand regulates pyrimidine ribonucleotide supply. In cancer, nucleotide metabolism can drive UDP-mediated macrophage cross-talk, which is subject to microenvironmental regulation. Additionally, PPARγ signaling enhances Treg responses through CD36/CPT1-mediated fatty acid oxidation and N-glycan branching, linking metabolic regulation to immune modulation.
cellular response to pyrimidine ribonucleotide and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NME6 | Mitochondrial gene expression and dysfunction | NME6 knockout and rescue in cancer cell lines |
| KRAS | KRAS G12C inhibitor resistance in cancer | KRAS G12C mutant cell lines with nucleotide cycling modulation |
| LPA4/LPA6 | Fluorouracil response in colon cancer | Colon cancer cells with LPA receptor knockout or overexpression |
| PPARγ | Treg-mediated immune regulation | T cell models with PPARγ modulation |
| A2AR | Immunotherapy resistance | Syngeneic tumor models with A2AR antagonism |
Cancer and immunotherapy resistance
Pyrimidine ribonucleotide metabolism is rewired in many cancers to support proliferation and immune evasion. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk that promotes immunosuppression and immunotherapy resistance. KRAS G12C inhibitors can be limited by nucleotide cycling, and overcoming this improves antitumor activity. RAS-GTP inhibition also shows anticancer activity in cholangiocarcinoma, highlighting nucleotide-linked signaling in cancer. A2AR antagonism can augment antitumor immunity, providing a strategy to counteract immunosuppression.
Mitochondrial dysfunction and metabolic disease
NME6-mediated ribonucleotide synthesis fuels mitochondrial gene expression, linking pyrimidine ribonucleotide responses to mitochondrial function. Disruption of this process could contribute to mitochondrial dysfunction. Cellular ATP levels influence fluorouracil sensitivity in colon cancer cells, indicating that energy metabolism intersects with pyrimidine ribonucleotide responses. PPARγ-driven fatty acid oxidation and N-glycan branching in Tregs further connect metabolic regulation to immune and inflammatory processes.
Antiviral responses and drug repurposing
Large-scale compound repurposing has identified modulators of nucleotide pathways as potential antiviral drugs against SARS-CoV-2. This suggests that cellular responses to pyrimidine ribonucleotides can influence viral replication and host defense. Understanding these responses may guide the development of host-directed antivirals.
From cellular response to pyrimidine ribonucleotide-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NME6 mediate mitochondrial gene expression via pyrimidine ribonucleotides? | NME6 knockout and knock-in cell lines |
| Does nucleotide cycling limit KRAS G12C inhibitor efficacy? | KRAS G12C mutant cells with point mutations in nucleotide cycling enzymes |
| Do LPA receptors modulate fluorouracil sensitivity? | LPA4/LPA6 knockout and overexpression colon cancer cells |
| Does PPARγ regulate Treg responses through metabolic pathways? | PPARγ knockout or overexpression T cells |
| Does A2AR antagonism overcome immunotherapy resistance? | A2AR knockout tumor models |
| Can nucleotide pathway modulators inhibit SARS-CoV-2? | Viral infection models with compound treatment |
How to Study the cellular response to pyrimidine ribonucleotide Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolomics | Levels of pyrimidine ribonucleotides | Quantify UTP/CTP changes after stimuli [2,8] |
| RNA-seq | Gene expression changes | Identify transcriptional responses including mitochondrial genes |
| CRISPR knockout screening | Genes required for drug response | Find modifiers of KRAS G12C inhibitor sensitivity |
| Cell viability assays | Drug sensitivity | Test fluorouracil or targeted inhibitor responses |
| Mitochondrial gene expression assays | Mitochondrial transcript levels | Assess NME6-dependent ribonucleotide synthesis |
| Macrophage co-culture | Immune cross-talk | Study UDP-driven immunosuppression |
| Antiviral assays | Viral replication | Evaluate nucleotide pathway modulators |
| Flow cytometry | Immune cell phenotypes | Analyze Treg or macrophage responses [3,7] |
Metabolomics and nucleotide quantification
Mass spectrometry-based metabolomics can quantify pyrimidine ribonucleotides such as UTP and CTP, revealing how cellular pools change in response to stimuli or genetic perturbations [2,8]. This method is essential to confirm that a stimulus actually alters pyrimidine ribonucleotide levels.
RNA-seq and mitochondrial gene expression analysis
RNA sequencing can measure changes in gene expression, including mitochondrial-encoded genes, following manipulation of pyrimidine ribonucleotide pathways. This helps identify downstream transcriptional responses that define GO:1905835.
CRISPR screening and functional genomics
CRISPR knockout screens can identify genes required for cellular responses to pyrimidine ribonucleotides, such as those involved in nucleotide cycling or drug sensitivity. Such screens link genotype to phenotype in a unbiased manner.
Drug sensitivity and synergy assays
Cell viability and synergy assays can test how modulation of pyrimidine ribonucleotide pathways affects responses to chemotherapies like fluorouracil or targeted inhibitors like KRAS G12C inhibitors [4,6]. These assays are critical for translational applications.
How CRISPR Can Be Used to Study GO:1905835 cellular response to pyrimidine ribonucleotide
Knockout
CRISPR knockout of genes such as NME6 or nucleotide cycling enzymes can reveal their requirement for cellular responses to pyrimidine ribonucleotides [4,8]. Knockout models help establish causality between a gene and the response.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to disable catalytic activity of enzymes involved in pyrimidine ribonucleotide metabolism. This allows precise structure-function studies.
Knock-in
Knock-in of tagged or reporter alleles can enable tracking of protein localization and dynamics during pyrimidine ribonucleotide responses. This is useful for understanding spatial and temporal regulation.
Overexpression
Overexpression of genes like NME6 or LPA receptors can test sufficiency in driving cellular responses to pyrimidine ribonucleotides [6,8]. Overexpression models complement knockout studies.
How EDITGENE Supports cellular response to pyrimidine ribonucleotide Research
Researchers studying cellular response to pyrimidine ribonucleotide-related genes often need to determine whether a candidate gene is causally involved in the response or merely correlated with it. CRISPR-based models provide the gold standard for such causal tests.
Contact EDITGENE today to design your custom CRISPR model for cellular response to pyrimidine ribonucleotide research.
Frequently Asked Questions About cellular response to pyrimidine ribonucleotide
What is GO:1905835?
GO:1905835 is the Gene Ontology term for cellular response to pyrimidine ribonucleotide, describing any cellular change caused by a pyrimidine ribonucleotide stimulus [2,8].
What are pyrimidine ribonucleotides?
They are RNA building blocks such as UTP and CTP that also act as signaling molecules in cells [2,8].
What genes are involved in cellular response to pyrimidine ribonucleotide?
Genes include NME6, KRAS, LPA receptors, PPARγ and nucleotide metabolism enzymes [3,4,6,8].
How is cellular response to pyrimidine ribonucleotide studied?
Researchers use metabolomics, RNA-seq, CRISPR screens and drug sensitivity assays [2,4,8].
Why is pyrimidine ribonucleotide metabolism important in cancer?
It supports proliferation and can drive immunosuppression and drug resistance [2,4].
What is the role of NME6 in this process?
NME6 synthesizes ribonucleotides needed for mitochondrial gene expression.
Can CRISPR knockout help study this process?
Yes, knockout of candidate genes can test their causal role in the response [4,8].
What diseases are linked to pyrimidine ribonucleotide responses?
Cancer, mitochondrial dysfunction and viral infections are linked [2,5,8].
How does nucleotide cycling affect KRAS G12C inhibitors?
Nucleotide cycling can limit drug efficacy, and overcoming it improves responses.
What services does EDITGENE offer for this research?
EDITGENE provides knockout, point mutation, knock-in, overexpression, library screening and bioinformatics services [4,6,8].
Conclusion
GO:1905835, cellular response to pyrimidine ribonucleotide, is a critical biological process that connects nucleotide metabolism to gene expression, immune regulation and mitochondrial function [2,8]. Its dysregulation is implicated in cancer, immunotherapy resistance and antiviral responses [2,4,5]. Studying this process with CRISPR models and multi-omics approaches can reveal new therapeutic targets. EDITGENE supports this research with comprehensive gene editing and screening services.
References
- 1. Entrialgo-Cadierno R et al.. 2026. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.. Cancer Cell 44(6):1218-1234.e7 PMID: 42030930
- 2. Scolaro T et al.. 2024. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance.. Nat Cancer 5(8):1206-1226 PMID: 38844817
- 3. Miao Y et al.. 2022. The activation of PPARγ enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TβRII/IL-2Rα.. Cell Commun Signal 20(1):48 PMID: 35392915
- 4. Zhang J et al.. 2024. D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities.. Cancer Discov 14(9):1675-1698 PMID: 38717075
- 5. Riva L et al.. 2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.. Nature 586(7827):113-119 PMID: 32707573
- 6. Takai M et al.. 2024. Impact of cellular ATP levels on cell viability in response to fluorouracil through lysophosphatidic acid (LPA) receptor-4 (LPA(4)) and LPA(6) in colon cancer cells.. Adv Biol Regul 93:101042 PMID: 39024813
- 7. Willingham SB et al.. 2018. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.. Cancer Immunol Res 6(10):1136-1149 PMID: 30131376
- 8. Grotehans N et al.. 2023. Ribonucleotide synthesis by NME6 fuels mitochondrial gene expression.. EMBO J 42(18):e113256 PMID: 37439264
